Prevalence of antibodies against a cyclic peptide mimicking the FG loop of the human papillomavirus type 16 capsid among Tunisian women

Elham Hassen
Laboratoire d’immuno-oncologie moléculaire, Faculté de Médecine de Monastir, 5019 Monastir, Tunisia
https://orcid.org/0000-0002-1387-4335

Devendra Bansal
Department of Microbiology and Immunology, Weill Cornell Medicine, Cornell University, Doha, Qatar

Randa Ghdira
Laboratoire d’immuno-oncologie moléculaire, Faculté de Médecine de Monastir, 5019 Monastir, Tunisia.

Anouar Chaieb
Service d’obstétrique et des maladies féminines, Hôpital Universitaire Farhat Hached, Sousse, Tunisie

Hedi Khairi
Service d’obstétrique et des maladies féminines, Hôpital Universitaire Farhat Hached, Sousse, Tunisie

Abdelfatteh Zakhama
Laboratoire d’anatomo-pathologie, Faculté de Médecine de Monastir, Monastir, Tunisie

Sami Remadi
Laboratoire CYTOPATH, Sousse, Tunisie

Johan Hoebeke
UPR9021 « Immunologie et Chimie Thérapeutiques, Institut de Biologie Moléculaire et Cellulaire, CNRS, Strasbourg, France.

Ali A Sultan
Department of Microbiology and Immunology, Weill Cornell Medicine, Cornell University, Doha, Qatar

Lotfi Chouchane (loc2008@qatar-med.cornell.edu)
Genetic Intelligence Laboratory, Weill Cornell Medicine-Qatar, Qatar Foundation, Doha, Qatar. https://orcid.org/0000-0002-2082-7924

Research

Keywords: HPV-16, antibodies, cyclic peptide, major capsid protein L1, and Tunisia

DOI: https://doi.org/10.21203/rs.3.rs-23621/v2

License: ☑️ This work is licensed under a Creative Commons Attribution 4.0 International License. Read Full License
Abstract

**Background** In the past decade, the cervical cancer rank went down from the second to the fourth most common cancer in women worldwide but remains ranked second in developing countries. High-risk types of human papillomavirus, mainly type 16, are the sexually transmitted agents etiologically linked to cervical cancer. The present study aimed to investigate the usefulness of a cyclic synthetic peptide designed from the major L1 capsid protein of the HPV16 for detecting anti-HPV16 antibodies.

**Methods** We designed and synthetized a peptide that corresponds to the full sequence of the surface-exposed FG loop. We tested against HPV16 L1 monoclonal antibodies the antigenicity of the linear and the cyclic peptides. Detection of anti-peptide antibodies was assessed by ELISA in sera and cervical secretions of 179 Tunisian women. For HPV DNA detection and genotyping, polymerase chain reaction and direct sequencing methods were applied.

**Results** Both the linear and the cyclic peptides were recognized by the same neutralizing monoclonal antibodies but the cyclic peptide was more reactive with human sera. In contrast to HPV16 DNA prevalence, the prevalence of the anti-peptide antibodies in sera was higher in women with low-grade squamous intraepithelial lesions (LGSIL) than in women with high-grade squamous intraepithelial lesions (HGSIL) (44% and 15%, respectively). Compared to women from the general population, systemic IgG prevalence was significantly higher among sex workers (25%; P=0.002) and women with LGSIL (44%; P=0.001). In addition, systemic IgA and cervical IgG prevalence was higher, only among sex workers (p=0.002 and P=0.001 respectively). We did not observe anti-peptide IgG antibodies in women with a current HPV16 infection.

**Conclusion** Anti-peptide IgG in sera or in cervical secretions could be markers of an effective natural immunization against the HPV16. This may open novel perspective for monitoring vaccinated women and for the design of synthetic peptide-based vaccine.

Background

Human papillomavirus (HPV) infection of the uterine cervix is a common sexually transmitted disease. Molecular epidemiological studies have identified the high risk-human papilloma virus infection as the major risk factor to develop cervical cancer and its precursors [1]. Cervical cancer, after breast cancer, is the second most common cancer in developing countries and remains one of the most frequently diagnosed malignant gynecological cancer worldwide with >570,000 new cases and 311,000 deaths in 2018 [2]. HPV types frequently associated with cervical cancer are classified as high-risk genotypes (16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, and 68), while those causing genital warts are designated low-risk HPV genotypes (6 and 11) [3]. HPV16 is the most frequent oncogenic type detected in both North-Africa as well as worldwide, while the other types are more frequent in Latin America and Alaska [4,5]. HPV infection with high-risk types may progress from infection to cervical lesions and cancer [6-9]. The progression of the pathogenesis from low-grade squamous intraepithelial lesions (LGSIL) to high-grade squamous intraepithelial lesions (HGSIL) and cervical cancer is an infrequent event [10], suggesting that the natural course of viral infection may be modulated by the immune response of each woman.

Papillomaviruses are non-enveloped DNA viruses, with an icosahedral capsid of approximately 55nm diameter. Their double stranded DNA genomes of 8.0kb encode Late and Early proteins (L1, L2, E1, E2, E4, E5, E6 and E7) [11-13]. Papillomaviruses capsid is composed of the two Late proteins, L1 and L2, the major capsid protein and the minor capsid protein, respectively. The expressed L1 protein self assembles into virus like particles (VLPs), which are morphologically and antigenically similar to native virions. Several studies have demonstrated that using HPV16 VLPs, a humoral response is developed against the viral capsid proteins [14-17]. The crystallography model of the HPV16 L1 protein predicts the existence of five loops (BC, DE, EF, FG, and HI) that are displayed on the surface of assembled capsomers [18]. All conformational epitopes identified to date using specific monoclonal antibodies have been found to reside on one or more hyper variable loops of the L1 protein [19-24].

In this study, we designed and synthesized a peptide corresponding to the FG loop of the major L1 capsid protein that includes residues implicated in the binding of neutralizing antibodies [20, 21]. The benefit of cyclized peptide over linear peptide has been
previously suggested, and because conformation has an important role in peptide antigenicity \[25, 26\], we applied the cyclization approach to the synthesized peptide. Using an Enzyme Linked Immunosorbent Assay (ELISA) based serological test we investigated the usefulness of the cyclic FG synthetic peptide for detecting HPV16 antibodies.

Methods

Study subjects

A total of 179 women including women with cervical lesion (n=43), legal sex workers (n=51) and general population (n=85) from Tunisia (North-Africa) were included in this study. Forty-three women with cervical lesions were recruited from the department of gynecology of Farhat-Hached Hospital, Sousse. This group includes different clinical stages of HPV lesions before any treatment. According to the Bethesda system for reporting of cervical cytology, women were classified into two lesion groups, LGSIL (n=16) and HGSIL (n=27). Fifty-one legal sex workers attending at monthly intervals The Primary Care of Sousse were included in this study. The study population, design and epidemiological information were described previously in detail \[27,28\]. Eighty-five women were randomly chosen from the general population, visiting the department of gynecology of Farhat Hached Hospital for routine gynecologic examination or to receive contraceptives. The three populations underwent a complete gynecologic examination, including a personal interview, a cervical smear for cytology, a blood sampling and a cervical sampling. The Ethical Commission of the Ministry of Public Health approved the study and all subjects who agreed to participate in this study gave informed consent.

Sample collection and cytologic evaluation

The cervical samples were collected with a cytobrush from the transformation zone of the cervix. After obtaining smears for cytology, the remaining cell samples with mucosal secretion on the brush were suspended in 1.5ml of Hanks buffer sterile solution (HBSS). After vortexing and centrifugation, the pellets were used for HPV DNA testing and the supernatants were stored at -70°C for IgG testing. Plasma samples obtained from heparinized blood were also stored at -70°C for further use. Before use, plasma was centrifuged at 10,000 rpm for 10 min at 4°C to remove debris. Smears were screened by the experienced cytopathologists and the final clinical diagnosis of the women with abnormal cytology was made by the histologic evaluation of biopsy samples obtained at colposcopy. Both cytologic and histologic diagnoses were performed according to the Bethesda system.

HPV DNA detection and sequencing

DNA was extracted using denaturation and precipitation with trimethyl-ammonium bromide salts method. The DNA pellet was dissolved in Tris-EDTA buffer and stored at -70°C. HPV DNA detection was carried out, as previously described \[27\]. Briefly, the presence of HPV DNA was performed using the L1 consensus degenerated primer (MY09/MY11) \[28\], which targets a conserved 450pb from the L1 ORF (open reading frame) and permits the detection of a large spectrum of genital HPV types. Each 20ml reaction contained 200mM of each dNTP, 10mM Tris hydrochloride (pH 8.3), 50mM potassium chloride and 1.5mM magnesium chloride; 80pmoles of each HPV L1 consensus degenerated primer; 8pmoles of each b-globin primer and 0.5 units of Taq polymerase (Amersham, Paris, France). The cycling conditions for PCR in an automatic thermal cycler (Biometra, Gottingen, Germany) include 30 cycles of denaturation at 94°C for 30 sec, annealing at 55°C for 60 sec, and extension at 72°C for 90 sec. The presence of human DNA was controlled in all samples by PCR amplification specific for the b-globin gene using the PCO3/PCO4 primers \[30\].

To identify HPV types, HPV-DNA positive samples were subjected to DNA sequencing. The gel purified L1-PCR products were sequenced using BigDyeDeoxy terminator cycle sequencing kit (BD V3.1, Applied Biosystems) according to the manufacturer’s instructions. The products were then purified on a separation column (AutoSeq™ G-50, Amersham Biosciences), and the templates were sequenced on an automated ABI-PRISM 310 Genetic Analyzer (Applied Biosystems). Sequence analysis was performed using nucleotide-nucleotide BLAST analysis (blatn) against known HPV genotypes stored in the GenBank database \[28\].
Peptide synthesis and cyclization

The synthesized peptide (L1FG/HPV16) was designed from the FG loop of the HPV 16 capsid protein L1. The sequence of the synthetic peptide is given in Table 1. To identify the possible HPV16 type restricted epitopes in the exposed FG loop, sequences of the most frequent detected HPV types (HPV16, 18, 6, 11, and 31) were aligned. The L1FG/HPV16 was assembled using Fmoc (9-fluorenylemethyloxycarbonyl) chemistry with a multichannel peptide synthesizer [31]. For cyclization of the L1FG/HPV16 a cysteine residue was added to the C-and N-terminus of the selected sequence peptide. After trifluoroacetic acid (TFA) cleavage, the peptides were purified by HPLC and their integrity was assessed by MALDI-TOF spectrometry. Cyclization of the L1FG/HPV16 was done at room temperature, overnight by air oxidation of the free thiol groups at 0.1mg/ml peptide in water, pH 7.5. The cyclized peptide was purified by HPLC and after lyophilization the cyclic peptide was characterized as above.

ELISA reactivity of neutralizing monoclonal antibodies to synthetic peptides

Three neutralizing monoclonal antibodies, H16.H5, H16.V5 and H16.E70 [19-21] (kindly provided by Dr. N.D. Christesen) were used to test peptide antigenicity. ELISA was prepared as follow, first the plates were coated with 500ng per well of the synthetic peptides in PBS (pH 9.7 for the non-cyclic peptide and pH 7.4 for the cyclized peptide) and incubated overnight at 4°C. Then wells were washed and blocked for 1 hour at 37°C with PBS containing 0.1% Tween-20 and 1% non-fat milk, next the plates were washed followed by addition of two by two dilution of the neutralizing monoclonal antibodies (from dilution 1:2 to 1:128) and incubated 1 hour at 37°C. After five washes, peroxidase-conjugated anti-mouse IgG diluted 1:2500 was added to the wells and incubated 1 hour at 37°C. After four washes with PBST and twice with PBS, the antibody binding was revealed by adding 3,3',5,5'-tetramethylbenzidine (TMB) in the presence of H₂O₂.

Antibody detection by ELISA

Antibodies against the synthetic peptides were quantified by ELISA. Briefly, 96 well microtiter plates (Griener, Microlon) were coated with 100ng of the synthetic peptide in PBS (pH 9.7 for the linear peptide and pH 7.4 for the cyclic peptide) per well and incubated at 4°C overnight. After washing with PBS-0.1 % Tween 20 (PBS-T), the wells were saturated with PBS-T supplemented with 1% gelatine (PBST-G) for 1 hour at 37°C. Duplicate wells, one test coated with peptide/PBS and one control with PBS, were incubated with human plasma, diluted 1:50 in PBS-T supplemented with gelatine 0.1 % (PBST-G) or undiluted cervical samples for 2 hours at 37°C. The plates were washed five times with PBS-T and bound antibodies were detected with a horseradish peroxidase-conjugated rabbit anti-human IgG or a horseradish peroxidase-conjugated rabbit anti-human IgA (Sigma, St. Louis, MO USA). For detection of secretory IgA (sIgA) in the cervical secretion a monoclonal anti-human secretory component and an anti-mouse IgG horseradish peroxidase-conjugated were used (Sigma, St. Louis, MO USA). Finally, the wells were washed three times with PBS-T and twice with PBS before revealing antibody binding by addition of ABTS (2,2-Azino-bis-[3-ethylbenzothiazoline-6sulfonic acid]) at 20mg/ml in 0.1 M sodium acetate buffer (pH 5) and H₂O₂ at 4mM. Absorbance was read at 405nm with an automated plate reader (Dynatech Laboratories MRX). The absorbance of each sample on PBS coated wells (control) was subtracted from that measured on peptide coated wells (test). To define antibody positive sera, the cutoff value was calculated separately for each peptide as the median of the specific absorbance values of all control sera plus 2.5 standard deviations excluding positive outliers. A corrected absorbance was considered positive at 0.1 or more for serum and 0.05 or more for cervical secretions.

Statistical Analysis

The Chi-square and the Fisher test were used to determine significant differences (p-value). Correlations was assessed using the Spearman rank test. A p-value of less than 0.05 was considered significant.

Results

Demographic, Clinic characteristics and risk factors of studied subjects

All the women enrolled in this study were from Tunisia. The age range across the studied population was 18 to 73 years with a mean age of 37 years. The majority of women from the general population or with cervical lesion (HGSIL and LGSIL) were
married (85%) and monogamous. The median age at first intercourse was found to be 19 years (ranges 12 to 27 years). This population was homogenous in terms of social habits. None of the women had history of using contraceptive or condoms systematically, smoking or drinking alcohol. Out of 43 women with cervical lesions, 16 were diagnosed as LGSIL and 27 as HGSIL. All the sex workers enrolled in the study were legal, relatively homogenous in terms of sexual activity and high exposure risk factors for HPV infection. Fourteen (27.4%) sex workers had experienced first intercourse before the age of 20. The mean of years of sex work was four years (ranging 0 to 16 years). Majority of sex workers reported smoking (n=45, 88.2%) and drinking alcohol (n=25, 49%). The condom use was reported as follow: 18 women (35%) never, 14 women (27%) sometimes and 19 (37%) all of the time.

**Binding of the peptides to the N-MAbs**

To demonstrate if the linear and the cyclic peptides are recognized by neutralizing antibodies we tested their antigenicity by using three specific monoclonal antibodies (MAbs) raised against the L1 capsid protein of the HPV16 (Fig. 1) [19-21]. The H16.H5 antibody, is a murine monoclonal antibody with no neutralizing activity or type specificity. H16.H5 is reactive to a linear epitope including residues from 174 to 185, in the EF loop [19,20]. The H16.V5 and the H16.E70 are both neutralizing antibodies that recognize conformational epitopes on the surface of HPV16 VLPs [21]. H16.V5 and H16.E70 recognize different epitopes on the surface of HPV16 VLPs, although there is some overlap in the residues recognized by the two antibodies localized at the FG loop. Both the FG and DE loops were necessary for binding of the H16.E70. While, the FG loop is the predominant epitope recognized by H16.V5 [21]. Compared to the H16.H5 and H16.E70 antibodies, the H16.V5 was the most reactive against both the linear and the cyclic peptides. Both peptides likely have comparable antigenicity against the H16.V5 antibody. The reactivity curves of the H16.H5 and H16.E70 antibodies were overlapped for each form of the peptides, but lower than H16.V5. However, the cyclic peptide was more reactive than the linear one with H16.H5 and H16.E70 antibodies (Fig. 1).

**Linear and cyclic peptide correlations**

To show if the two shapes of the peptide (linear and cyclic) have the same antigenicity to human sera, we tested the two peptides against sera samples from the several group of the study population. Pearson correlation analysis of the ELISA optical density results (405nm) for IgG detection using linear or cyclic peptide showed no significant correlation (r=-0.036; p=0.830) (Fig. 2). Unlike what we observed with mouse Mab, the two shapes of the peptides seem to react differently when binding to human polyclonal antibodies. The cyclic peptide is more reactive with human sera. This difference in reactivity, may have several reasons. First, antibodies in human sera are directed against a larger panel of epitopes. Secondly, cyclic peptides are known to be more stable than linear peptides with identical amino acid sequence. They are especially resistant to hydrolysis by exopeptidase as they lack amino and carboxyl ends. Besides, the rigidity of cyclic peptides increases binding affinity which can extend their biological activity and improve recognition of epitope mimics [32,33]. For all these reasons, only results obtained with the cyclic peptide were presented below.

**Detection of systemic and cervical anti-L1FG/HPV16 antibodies**

The distribution of positive women to anti-L1FG/HPV16 antibodies is summarized in Table 2. For statistical analysis, the reference group was the healthy women from the general population. The systemic IgG antibody prevalence was significantly higher among women with LGSIL and sex workers (44% and 25%, respectively). However, comparable frequencies were observed among women with HGSIL and those from the general population (15% and 12%, respectively). The systemic IgA and the cervical IgG antibody prevalence's were significantly more elevated among the sex workers, suggesting the influence of the lifestyle on antibody production (23% and 16%, respectively).

Compared to healthy women from the general population, the HPV DNA prevalence was significantly higher among sex workers and women with LGSIL or HGSIL (39%, 62%, and 81%, respectively) (Table 2). As antibodies are a marker of past as well as present infection, we examined the relationship between HPV16 capsid FG loop reactivity and the status of HPV16 infection (Table 3). The overall frequency of HPV16 DNA positivity was 13% (23/179), interestingly none of the HPV16 positive women showed positive systemic or local IgG anti-peptide antibodies. However, among HPV16 DNA negative women but infected by HPV types other than the HPV16 (HPV18, 31, 33, 45, 56, 58, 68, 82, 53, 66, 6, 11, 61, 70, 81, 83 and 84) [28], we detected a higher
antibody prevalence in both sera and cervical secretions. These results suggesting that detection of anti-L1FG/HPV16 IgG antibodies is unrelated to a current infection with HPV16.

To identify a prognostic signification of the anti-L1FG/HPV16 antibodies, we extended our analysis and compared results of LGSIL and HGSIL patients. The proportion of local IgG and IgA was very low in cervical samples and could not be compared. However, in sera, the frequency of the antibodies was significantly more elevated among women with LGSIL compared to HGSIL (44% versus 15%; \( p=0.04 \)), suggesting that women with anti-peptide antibodies appear to have a better prognosis than those without antibodies.

We have previously shown that HPV infection decreased with age, among healthy women [27,28]. To assess if we observed the same pattern with the antibody reactivity to the L1FG/HPV16, we overlapped HPV DNA and IgG prevalence’s curves according to age (Fig. 3). Among healthy women from the general population, the HPV DNA and IgG prevalence’s were less than 20% and did not change significantly with age. Among the sex workers, the prevalence of systemic IgG increases (21% to 66%), and conversely HPV DNA prevalence decreased (54% to 25%) from the age of 31 years old. Among the women with cervical lesions, HPV DNA prevalence remained elevated, but prevalence of systemic IgG markedly decreased from the age of 31 years old. Altogether, when we compare the pattern among sex workers and women with cervical lesions, we observed inverted and positive progress, suggesting that anti-L1FG/HPV16 antibodies may have efficient effect on HPV clearance.

**Discussion**

To date, several studies have used linear synthetic peptides to detect antibodies against the HPV L1 protein [34-37]. However, these studies have used linear synthetic peptides. The FG loop is a hyper variable region exposed on the outer surface of the capsid. Several residues in the FG loop were involved in the binding of neutralizing antibodies [20, 21, 38]. On the basis of these findings, we looked for an amino-acid sequence that could account for a specific epitope into the HPV16 L1 protein. Therefore, the FG loop sequences from the detected HPV types (HPV16, 18, 31, 6 and 11) were aligned (Table 1). After determining the percentage of amino acid identity, we selected and synthesized a shorter sequence including 25 residues. It was previously shown that conformation seems to have an important role in peptide antigenicity. The antigenicity of the two forms of the FG peptide was shown by binding to the neutralizing monoclonal antibody H16.V5. The H16.V5 is a HPV16 murine monoclonal antibody, and its neutralizing activity was described before the publication of the crystallography model of the HPV16 L1 protein [21]. Through a cryo-electron microscopy study on VLP capsid, 17 residues have been found to bound to the H16.V5 Mab, 8 out the 17 bound to the FG loop (Table 1), two bound the BC and DE loops of the same L1 protein, and three and two bound the DE and HI loops of the adjacent L1 protein [39]. However, the characterization of a human neutralizing antibody 26D1, showed some distinct neutralizing epitopes from that of H16.V5. The 26D1 human monoclonal antibody recognizes a conformational epitope that partially overlaps that of H16.V5. Regarding the FG loop, out of the 8 binding residues of the H16.V5, only three residues were overlapping with the 26D1, suggesting that human neutralizing monoclonal antibodies could have different interaction with the VLP capsid [24]. To obtain the best mimic of the FG loop, we added two cysteine residues at the N- and C-terminus of the peptide and we applied a cyclization step. As suggested by molecular modeling, the cyclization of the FG linear peptide might induce the native conformation of the FG loop. Moreover, cyclic peptides are more resistant to hydrolysis by peptidase and more rigid to ensure better affinity and recognition of epitope mimics [32,33]. When we tested the antigenicity of the linear and the cyclic peptides with human sera, and we compared the reactivity of the linear peptide and the cyclic peptide, results did not match between the two peptides. The difference in stability and rigidity between the two peptides could be the cause that confirms the importance of cyclization.

Antibodies raised against the cyclic FG loop in women sera and cervical secretions were quantified using ELISA. The highest seroprevalence for the systemic IgG was found in women with LGSIL, 44%. However, women with HGSIL showed a seroprevalence of 15%, which is comparable to that observed among healthy women (12%). In an earlier study, using a linear peptide from residues 267 to 286, weak reactivity was observed in the sera of HPV16 infected women with cervical lesions [34]. In addition, antibodies against L1 peptide from residues 279 to 293 were detected in sera of patients with cervical lesions but did not correlate with HPV16 DNA [35]. The low seroprevalence against the peptide in women with high-grade lesions might be due to the decrease of the L1 expression. Indeed, it is known that L1 protein expression *in vivo* is usually restricted to low-grade
lesions [40]. The transcription of the L1 gene is restricted to differentiated keratinocytes and the level of L1 expression decreases with the grade of the cervical lesions [41]. These findings indicate that the seroprevalence to these L1 epitopes is unlikely to have a prognostic value.

Interestingly, whatever the women group, in all the HPV16 DNA positive we did not observe positive IgG in sera or cervical secretion samples. However, women without HPV infection or infected with other HPV types showed prevalence of 22% and 7% in sera and cervical secretion, respectively. A more likely explanation is that seropositive women have been infected previously by the HPV16 and that the antibodies detected were those that persist after the virus has been eliminated by the immune system. In contrast, seronegative and HPV16 DNA positive women were likely unable to produce antibodies against the FG loop. These findings suggest that the anti-L1FG/HPV16 antibodies could have efficient effect on HPV16 infection. Anti-L1FG/HPV16 IgG antibodies in sera or in cervical secretions could be markers of an effective natural immunization against the HPV16. Previous observation clearly established that the FG loop contains neutralizing epitopes [42, 43], and a cell-binding region used by HPV for invading target cells [44], together with our results could incite for more investigation on peptide helpfulness in HPV related infection.

Since secretory IgA provides the first line of defense against pathogens invading mucosae, the levels of these antibodies may provide a better indicator of HPV infection. Several reports, using HPV16 VLPs as antigen, suggest that the cervical IgA response reflects current HPV infection [45-48]. However, in this study, positivity was not significantly different and among the twenty-three HPV16 DNA positive women, only one was positive for the secretory IgA. This dissimilarity may be due to the fact that anti-VLP antibodies were directed against multitude conformational epitopes including those directed against the L1FG/HPV16, meaning that an anti-peptide HPV negative woman could be anti-VLP positive [49]. An alternative explanation is that, in previous reports [45-48] total IgA was detected in the cervical secretions, herein we quantified only secretory IgA.

We previously demonstrated that the prevalence of HPV infection is strongly associated with risk factors like sexual activity and age [27,28]. To find out whether the presence of antibodies was also influenced by these risk factors, antibody response of women with lesions, sex workers and women from the general population were compared. The positivity of serologic IgA and cervical IgG was found to be significantly higher in sex workers, than in women with lesions or from general population. Suggesting that lifestyle could impact HPV antibodies production. Besides, the IgG response tended to decrease with age in women with cervical lesion and increase in legal sex workers, whereas the prevalence of HPV DNA detection remained the same in women with cervical lesions and decreased in legal sex workers (Figure 3). In previous study, we found that the decrease in HPV DNA positivity with increasing age was independent of sexual activity but could be related to the development of an efficient immune response acquired with age [27,28]. Here, unlike the women with cervical lesion, the increase of anti-HPV16 IgG responses with increasing age noticed in the sex workers corroborates this theory. Sex workers have a high number of sexual partners and repeated risk of HPV infection that may stimulate an anti-HPV immune response that leads to the production of antibodies.

To sum up, using the L1FG/HPV16 peptide as a capture antigen (i) low IgG seroprevalence was observed among women with HGSIL; (ii) null IgG seroprevalence was noted among women carrying the HPV16; and (iii) an increasing IgG seroprevalence was accompanied by a decrease in HPV16 DNA prevalence in women at high risk of exposition to HPV. Taken together these observations comfort the hypothesis that anti-peptide antibodies could be a marker of good prognostic for the disease and protection for the infection. However, for a better estimation of the usefulness of the L1FG/HPV16 we need to conduct the study on vaccinated women and women with cervical carcinoma.

Conclusions

To the best of our knowledge, this is the first report using a cyclic peptide of the full-length FG loop sequence of the HPV16 L1 protein. The HPV16 is the most prevalent oncogenic HPV type in high grade cervical lesion, while the studied population size needs to be increased, we found that all the women developing high grade cervical lesion caused by the HPV16 failed to produce anti-L1FG/HPV16 antibodies. These findings could also have obvious implications for the development of L1 polycyclic peptide
or new molecular scaffold for peptides that could be an attractive perspective for ELISA testing and cyclic peptide-based vaccine [33,50].

**Abbreviations**

HPV: Human Papilloma Virus; HR: High-risk; HGSIL: High-Grade Squamous Intraepithelial Lesion; LGSIL: Low-Grade Squamous Intraepithelial Lesion; ELISA: Enzyme Linked Immunosorbent Assay; HBSS: Hanks buffer sterile solution; ORF: open reading frame.

**Declarations**

**Ethics approval and consent to participate**

Ethical clearance was obtained from the Ethical Commission of the Ministry of Public Health and all subjects who agreed to participate in this study gave informed consent.

**Consent for publication**

Not Applicable

**Competing interests**

The authors declare that they have no competing interests.

**Funding**

This work was supported by les Ministéres de L'Enseignement Supérieur et de la Santé Publique de la République tunisienne and by NPRP grant #09-344-3-082 from the Qatar National Research Fund (a member of Qatar Foundation).

**Author Contributions**

Conceptualization and study design : EH, JH, AAS, and LC; clinical data and specimen collection, HK, AC, AZ, SR ; Analysis : EH, RG, DB ; Manuscript Preparation, EH, JH, DB, AAS and LC.

**Acknowledgments**

Not Applicable

**Availability of data and material**

The datasets used and/or analysed during the current study and patient information sheet are available from the corresponding author on reasonable request.

**References**

1. IARC: Human Papillomaviruses. In Human Papillomaviruses, Volume 64. Lyon, France: IARC; 1995.
2. https://www.who.int/news-room/fact-sheets/detail/human-papillomavirus-(hpv)-and-cervical-cancer. Accessed on 15 February 2020.
3. Doorbar J, Egawa N., Griffin H., Kranjec C., Murakami I. Human papillomavirus molecular biology and disease association Rev. Med. Virol., 25 (Suppl. 1) (2015), pp. 2-23.
4. Sebbelov AM, Davidson M, Kruger Kjaer S, Jensen H, Gregoire L, Hawkins I, et al. Comparison of human papillomavirus genotypes in archival cervical cancer specimens from Alaska natives, Greenland natives and Danish Caucasians. Microbes
Bychkovsky BL, Ferreyra ME, Strasser-Weippl K, Herold CI, de Lima Lopes G Jr, Dizon DS Schmeler, et al. Cervical cancer control in Latin America: A call to action. Cancer. 2016; 122 (4): 502-514.

Kiviat NB, Koutsky LA, Paavonen JA, Galloway DA, Critchlow CW, Beckmann AM, et al. Prevalence of genital papillomavirus infection among women attending a college student health clinic or a sexually transmitted disease clinic. J Infect Dis. 1989; 159 (2): 293-302.

Bauer HM, Ting Y, Greer CE, Chambers JC, Tashiro CJ, Chimera J, et al. Genital Human papilloma virus infection in female university students as determined by a PCR based method. JAMA. 1991; 265(4): 472-477.

Munoz N. Human papillomavirus and cancer: the epidemiological evidence. J Clin Virol. 2000; 19(1-2): 1-5.

Álvarez-Paredes L, Santibañez M, Galiana A, Rodríguez Díaz JC, Parás-Bravo P, Andrade-Becerra ME, et al. Association of Human Papillomavirus Genotype 16 Viral Variant and Viral Load with Cervical High-grade Intraepithelial Lesions. Cancer Prev Res (Phila). 2019; 12(8): 547-556.

Oyervides-Muñoz MA, Pérez-Maya AA, Rodríguez-Gutiérrez HF, Gómez-Macias GS, Fajardo-Ramírez OR, Treviño V, et al. Understanding the HPV integration and its progression to cervical cancer. Genet Evol. 2018; 61: 134-144.

Favre E. Structural polypeptides of rabbit, bovine and human papillomavirus. J Virol. 1975;15(5):1239-47.

Burk RD, Chen Z, Saller C, Tarvin K, Carvalho AL, Scapulatempo-Neto C. Integrated genomic and molecular characterization of cervical cancer. Nature 2017; 543(7645): 378–384.

Godi A, Bissett SL, Miller E, Beddows S. Relationship between Humoral Immune Responses against HPV16, HPV18, HPV31 and HPV45 in 12-15 Year Old Girls Receiving Cervarix® or Gardasil® Vaccine. PLoS One 2015; 10(10): e0140926.

Giannini SL, Hanon E, Moris P, Van Mechelen M, Morel S, Dessy F, et al. Enhanced humoral and memory B cellular immunity using HPV16/18 L1 VLP vaccine formulated with the MPL/aluminium salt combination (AS04) compared to aluminium salt only. Vaccine 2006; 24(33-34): 5937-5949.

Chen XS, Garcea RL, Goldberg I, Casini G, Harrison SC. Structure of small virus-like particles assembled from the L1 protein of human papillomavirus 16. Mol Cell. 2000; 5(3): 557-567.

Christensen ND, Dillner J, Eklund C, Carter JJ, Wipf GC, Reed CA, et al. Surface conformational and linear epitopes on HPV-16 and HPV-18 L1 vims like particles as defined by monoclonal antibodies. Virology. 1996; 223(1): 174-184.

Rodent RB, Annstrong A, Haderer P, Christensen ND, Hubbert NL, Lowy DR, et al. Characterization of a human papillomavirus type 16 variant-dependent neutralizing epitope. J Virol. 1997; 71(8): 6247-6252.

White WI, Wilson SD, Palmer-Hill FJ, Woods RM, Ghim SJ, Hewitt LA, et al. Characterization of a major neutralizing epitope on human papillomavirus type 16 L1. J Virol. 1999; 73(6): 4882-4889.

Fleury MJ, Touzé A, Maurel MC, Moreau T, Coursaget P. Identification of neutralizing conformational epitopes on the human papillomavirus type 31 major capsid protein and functional implications. Protein Sci. 2009; 18(7): 1425-1438.

Zhang X, Li S, Modis Y, Li Z, Zhang J, Xia N, et al. Functional assessment and structural basis of antibody binding to human papillomavirus capsid. Rev Med Virol, 2016; 26(2): 115-128.

Xia L, Xian Y, Wang D, Chen Y, Huang X, Bi X, et al. A human monoclonal antibody against HPV16 recognizes an immunodominant and neutralizing epitope partially overlapping with that of H16.V5. Sci Rep. 2016; 6: 19042.

Muller S, Plaue S, Samama JP, Vallette M, Briand JP, Van Regenmortel MHV. Antigenic properties and protective capacity of a cyclic peptide corresponding to site A of influenza vims Haemagglutinin. Vaccine 1990; 8(4): 308-314.
26. Valero ML, Camarero JA, Haack T, Mateu MG, Domingo E, Giralt E, et al. Native-like cyclic peptide models of viral antigenic site: finding a balance between rigidity and flexibility. J Mol Recognit. 2000; 13(1): 5-13.

27. Hassen E, Chaieb A, Letaief M, Khairi H, Zakhama A, Remadi S, et al. Cervical human papillomavirus infection in Tunisian women. Infection. 2003; 31(3): 143-148.

28. Ghedira R, Mahfoudh W, Hadhri S, et al. Human papillomavirus genotypes and HPV-16 variants distribution among Tunisian women with normal cytology and squamous intraepithelial lesions. Infect Agent Cancer. 2016;11:61.

29. Ting Y, Manos MM. Detection and typing of genital human papillomavirus. In: PCR protocols: a guide to methods and applications, edited by Innis MA, Gelfand DH, Snisky JJ, White TJ. Academic press, San Diego. 1989: 356-367.

30. Saiki RK, Schalf S, Falloona F, Mullis KB, Hom GT, Erlich HA, et al. Enzymatic amplification of beta-globin genomic sequences and restriction site analysis for diagnosis of sickle cell anemia. Science. 1985; 230(4732): 1350-1354.

31. Neimark J, Briand JP. Development of a fully automated multichannel peptide synthesizer with an integrated TFA cleavage capability. Peptide Res. 1993; 6(4): 219-228.

32. Joo SH. Cyclic peptides as therapeutic agents and biochemical tools. Biomol Ther (Seoul). 2012;20(1):19-26.

33. Meuleman TJ, Dunlop JI, Owsianka AM, van de Langemheen H, Patel AH, Liskamp RMJ. Immobilization by Surface Conjugation of Cyclic Peptides for Effective Mimicry of the HCV-Envelope E2 Protein as a Strategy toward Synthetic Vaccines. Bioconjug Chem. 2018;29(4):1091-1101.

34. Ting Y, Manos MM. Detection and typing of genital human papillomavirus. In: PCR protocols: a guide to methods and applications, edited by Innis MA, Gelfand DH, Snisky JJ, White TJ. Academic press, San Diego. 1989: 356-367.

35. Le Cann P, Chabaud M, Leboulleux D, Mougin C, Mayelo V, Legrand MC, et al. Detection of antibodies to LI, L2, and E4 proteins of human papillomavirus types 6,11, and 16 by ELISA using synthetic peptides. J Med Virol. 1995; 145(4): 410-414.

36. Bissett SL, Godi A, Beddows S. The DE and FG loops of the HPV major capsid protein contribute to the epitopes of vaccine-induced cross-neutralizing antibodies. Sci Rep. 2016; 6: 39730.

37. Lee H, Lee KJ, Jung CK, Hong JH, Lee YS, Choi YJ, et al. Expression of HPV L1 capsid protein in cervical specimens with HPV infection. Diagn Cytopathol. 2008; 36(12): 864-867.

38. Graham SV. Human papillomavirus: gene expression, regulation and prospects for novel diagnostic methods and antiviral therapies. Future Microbiol. 2010;5(10):1493-1506.

39. Slupetzky K, Shafi-Keramat S, Lenz P, Brandt S, Grassauer A, Sara M, et al. Chimeric papillomavirus-like particles expressing a foreign epitope on capsid surface loops. J Gen Virol. 2001; 82: 2799-2804.

40. Sadeyen JR, Tourne S, Shkreli M, Sizaret PY, Coursaget P. Insertion of a foreign sequence on capsid surface loops of human papillomaviruses type 16 vims-like particles reduces their capacity to induce neutralizing antibodies and delineates a conformational neutralizing epitope. Virology. 2003; 309(1): 32-40.

41. Vera-bravo R, Ocampo M, Urquiza M, Garcia JE, Rodriguez LE, Puentes A, et al. Human papillomavirus type 16 and 18 LI protein peptide binding to VERO and HeLa cells inhibits their VLPs binding. Int J Cancer. 2003; 107(3): 416-424.

42. Wang Z, Hansson BG, Forslund O, Dillner L, Sapp M, Schiller JT, et al. Cervical mucus antibodies against human papilloma virus type 16, 18, and 33 capsids in relation to presence of viral DNA. J. Clin. Microbiol. 1996; 34(12): 3056-3062.

43. Sasagawa T, Yamasuki H, Dong YZ, Satake S, Tateno M, Inoue M. Immunoglobulin-A and G responses against virus like particles of human papillomavirus type 16 in women with cervical cancer and cervical intra-epithelial lesions. Int J Cancer 1998; 75(4): 529-535.
47. Bontkes HJ, De Gruijl TD, Walboomers JMM, Schiller JT, Dillner J, Helmerhorst TJM, et al. Immune responses against human papillomavirus type 16 virus-like particles in a cohort study of women with cervical intraepithelial neoplasia. J Gen Virol. 1999; 80: 409-417.

48. Sasagawa T, Rose RC, Azar KK, Sakai A, Inoue M. Mucosal immunoglobulin-A and G responses to oncogenic human papillomavirus capsids. Int J Cancer. 2003; 104(3): 328-335.

49. Rocha-Zavaleta L, Yescas G, Cmz RM, Cruz-Talonia F. Human papillomaviruses infection and cervical ectopy. Int J Gynecol Obstet. 2004; 85(3):259-266.

50. Malonis RJ, Lai JR, Vergnolle O. Peptide-Based Vaccines: Current Progress and Future Challenges. Chem Rev. 2020;120(6):3210-3229.

**Tables**

Table 1: Alignment of amino acid sequences corresponding to the HPV16 linear selected peptide

| Papi | ilom | avir | us   | Residues in bold designed contact amino acids to H16.V5 [39]; Residues underlined designed overlapping amino acids to H16.V5 and 26D1 [24]. |
|------|------|------|------|----------------------------------------------------------------------------------|
| 266  | H    | T    | V    | G    | E    | N    | V    | P    | D    | D    | L    | Y    | I    | K    | G    | S    | G    | S    | T    | A    | N    | L    | A    | S    | S    | N    | 10  |
| PV   | 16   |      |      |      |      |      |      |      |      |      |      |      |      |      |      |      |      |      |      |      |      |      |      |      |      |      |     |
| 282  | H    | _    | M    | _    | D    | T    | _    | _    | Q    | S    | _    | _    | _    | _    | _    | _    | _    | _    | _    | _    | T    | _    | _    | N    | _    | T    | 84  |
| PV   | 18   |      |      |      |      |      |      |      |      |      |      |      |      |      |      |      |      |      |      |      |      |      |      |      |      |      |     |
| 290  | H    | _    | _    | _    | _    | _    | _    | _    | _    | _    | _    | _    | _    | _    | _    | _    | _    | _    | _    | _    | T    | _    | _    | N    | _    | T    | 84  |
| PV   | 31   |      |      |      |      |      |      |      |      |      |      |      |      |      |      |      |      |      |      |      |      |      |      |      |      |      |     |
| 290  | H    | _    | _    | _    | _    | _    | _    | _    | _    | _    | _    | _    | _    | _    | _    | _    | _    | _    | _    | _    | T    | _    | _    | N    | _    | T    | 84  |
| PV   | 11   |      |      |      |      |      |      |      |      |      |      |      |      |      |      |      |      |      |      |      |      |      |      |      |      |      |     |
| 266  | H    | _    | _    | _    | _    | _    | _    | _    | _    | _    | _    | _    | _    | _    | _    | _    | _    | _    | _    | _    | T    | _    | _    | N    | _    | T    | 84  |
| PV   | 11   |      |      |      |      |      |      |      |      |      |      |      |      |      |      |      |      |      |      |      |      |      |      |      |      |      |     |

Table 2: Distribution of anti-L1FG/HPV16 IgG and IgA antibodies

| HPV DNA Systemic IgG | Systemic IgA | Cervical IgG | Cervical sIgA |
|----------------------|--------------|--------------|---------------|
| n/total (%) | p value | n/total (%) | p value | n/total (%) | p value | n/total (%) | p value |
| General population * | 14/85 (16) | 10/85 (12) | 5/85 (6) | 1/85 (1) | 3/85 (3) |
| Sex workers | 20/51 (39) | 0.005 | 13/51 (25) | 0.002 | 12/51 (23) | 0.002 | 8/51 (16) | 0.001 | 4/51 (8) | 0.2 |
| LGSIL | 10/16 (62) | 0.0004 | 7/16 (44) | 0.001 | 3/16 (19) | 0.1 | 2/62 (12) | 0.006 | 1/62 (5) | 0.5 |
| HGSIL | 22/27 (81) | < 0.0001 | 4/27 (15) | 0.4 | 4/27 (15) | 0.1 | 0/27 (0) | 0.7 | 0/27 (0) | 0.4 |

* Reference group; LGSIL: low grade squamous intraepithelial lesions; HGSIL: high grade squamous intraepithelial lesions.
Table 3: Distribution of anti-L1FG/HPV16 IgG and IgA antibodies according to HPV infection

| HPV DNA          | Systemic IgG | Systemic IgA | Cervical IgG | Cervical sIgA |
|------------------|--------------|--------------|--------------|---------------|
|                  | n/total (%)  | n/total (%)  | p value      | n/total (%)  | p value      | n/total (%)  | p value      | n/total (%)  | p value      |
| negative *       | 111/179 (62) | 22/111 (20)  |              | 12/111 (11)  |              | 5/111 (4)    |              | 5/111 (4)    |              |
| HPV DNA positive |              |              | 0.3          |              | 0.2          |              | 0.05         |              | 0.6          |
| HPV16 negative  | 45/179 (25)  | 12/45 (27)   |              | 8/45 (18)    |              | 6/45 (13)    |              | 2/45 (4)     |              |
| HPV16 positive  | 23/179 (13)  | 0/23 (0)     | 0.01         | 4/23 (17)    | 0.2          | 0/23 (0)     | 0.3          | 1/23 (4)     | 0.7          |

* Reference group; § HPV positive for the following types: HPV18, 31, 33, 45, 56, 58, 68, 82, 53, 66, 6, 11, 61, 70, 81, 83 and 84 [28].

Figures
Figure 1

Monoclonal antibody activity against the linear (squares) and the cyclic (circles) of the L1FG/HPV16 peptides.

Figure 2

Correlation between linear and cyclic peptide ELISAs for IgG capture from women sera (absorbance at 405nm). Pearson's Correlation Coefficient, $r = -0.036; p = 0.830$. 
Figure 3

Frequencies of IgG antibodies in sera (squares), in cervical secretions (triangles) and DNA prevalence (diamonds) in all age groups in the women of the study: (A) healthy women; (B) sex workers; (C) women with cervical lesions.